Compare Franklin Resources, Inc. (BEN) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? Franklin Resources, Inc. trades at $33.37 (market cap $16.95B), while Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $505.73M). The key difference: Franklin Resources, Inc. is far larger — about 33.5× Ginkgo Bioworks Holdings Inc's market cap, and Franklin Resources, Inc. pays a 3.96% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| BEN | DNA | |
|---|---|---|
Market Cap | $16.95B | $505.73M |
Sector | Financials | Health |
52-Week High | $35.77 | $16.14 |
52-Week Low | $21.18 | $5.48 |
Enterprise Value | $29.90B | $607.68M |
Dividend Yield | 3.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
